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Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summary of the
effects of blood glucose-lowering drugs other than glitazones on the risk of heart failure in routine clinical practice
is lacking. The objective of this study was to conduct a systematic review and meta-analysis of observational studies
on the risk of heart failure when using blood glucose-lowering drugs.
Methods: We systematically identified and reviewed cohort and case–control studies in which the main exposure
of interest was noninsulin blood glucose-lowering medications in patients with T2DM. We searched Medline, Embase,
and the Cochrane Library to identify publications meeting prespecified eligibility criteria. The quality of included
studies was assessed with the Newcastle-Ottawa Scale and the RTI item bank. Results were combined using fixed
and random-effects models when at least 3 independent data points were available for a drug-drug comparison.
Results: The summary relative risk of heart failure in rosiglitazone users versus pioglitazone users (95% CI) was
1.16 (1.05-1.28) (5 cohort studies). Heterogeneity was present (I2 = 66%). For new users (n = 4) the summary
relative risk was 1.21 (1.14-1.30) and the heterogeneity was reduced (I2 = 31%);. The summary relative risk for
rosiglitazone versus metformin was 1.36 (95% CI, 1.17-1.59) (n = 3). The summary relative risk (95% CI) of heart
failure in sulfonylureas users versus metformin users was 1.17 (95% CI, 1.06-1.29) (5 cohort studies; I2 = 24%) and
1.22 (1.02-1.46) when restricted to new users (2 studies).
Information on other comparisons was very scarce. Information on dose and duration of treatment effects was
lacking for most comparisons. Few studies accounted for disease severity; therefore, confounding by indication
might be present in the majority of the within-study comparisons of this meta-analysis.
Conclusions: Use of glitazones and sulfonylureas was associated with an increased risk of heart failure compared
with metformin use. However, indication bias cannot be ruled out. Ongoing large multidatabase studies will
help to evaluate the risk of heart failure in treated patients with diabetes, including those using newer blood
glucose-lowering therapies.
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Progressive loss of the insulin secretory capacity of the
pancreatic beta cells and insulin resistance are the two
mechanisms involved in the pathophysiology of type 2
diabetes mellitus (T2DM) [1]. Earlier medications for
the treatment of T2DM were targeted to stimulate or re-
place endogenous insulin secretion. Newly developed
agents are indirectly or directly targeted to treat insulin
resistance, which usually precedes the clinical manifesta-
tions of diabetes. Insulin resistance, a state in which a
given concentration of insulin is associated with a sub-
normal glucose response [2], and diabetes are both asso-
ciated with an increased risk of cardiovascular disease
and are often accompanied by a constellation of other
cardiovascular risk factors. In fact, T2DM has been con-
sidered as equivalent to coronary heart disease for car-
diovascular risk prediction and prevention [3,4]. Therefore,
newer medications are intended not only to control hyper-
glycemia and reduce the risk of microvascular complica-
tions but also to reduce the risk of macrovascular
complications [5]. However, as it has been also pointed out
by others, “therapies for diabetes mellitus have not trad-
itionally been rigorously evaluated for the risk of develop-
ing incident or worsening heart failure” [6].
The glitazones, with a predominant mechanism of ac-
tion on peroxisome proliferator-activated receptor-γ
genes, were considered as potentially having additional
clinical benefit due to their insulin-sensitizing effect.
Fluid retention was identified among the safety con-
cerns before approval, but other cardiovascular safety
concerns arose after their availability in 2000. The
European Medicines Agency (EMA) suspended the
authorization of rosiglitazone in September 2010 due to
concerns about the associated increased risk of acute
coronary syndrome, while the United States (USA)
Food and Drug Administration (FDA) imposed a re-
stricted prescription program in November 2011 [7].
Two years later, the FDA lifted its earlier restrictions after
reviewing the results of the 2009 RECORD clinical trial,
which did not show any increase in the risk of acute myo-
cardial infarction associated with the drug [8].
Patients with T2DM are at high risk of heart failure
due to the coexistence of diabetes with other risk factors
such as hypertension, ischemic heart disease, and kidney
function decline and because the diabetic myocardium
might be more sensitive to the deleterious effect of car-
diovascular risk factors [9]. Diabetes is a strong predictor
of incident heart failure [10]. Almost 40% of patients
hospitalized for acute decompensated heart failure have
diabetes [11]. In the context of T2DM, once heart failure
is present, the patient’s prognosis is poor [12]. The risk
of heart failure associated with blood glucose-lowering
medications may arise as an undesired effect of the
drugs or as a consequence of their lack of effectiveness.For example, glitazones are associated with weight gain
and fluid retention leading to edema, which might trig-
ger the development of congestive heart failure in pre-
disposed patients. Poor glycemic control in patients with
T2DM is also associated with increased risk of heart fail-
ure [13,14].
The 2012 joint clinical guidelines of the American Dia-
betes Association (ADA) and the European Association
for the Study of Diabetes (EASD) emphasized that the
choice of blood glucose-lowering agent should focus on
drug safety, especially protecting against hypoglycemia,
heart failure, renal dysfunction, bone fractures, and
drug-drug interactions [15]. However, clinical guidelines
have changed over time. Metformin and rosiglitazone
were both initially contraindicated in patients with heart
failure. In the case of metformin, this contraindication
was due to the potentially increased risk for lactic acid-
osis, which was why the related drugs phenformin and
buformin were removed from the market. At present,
metformin is being recommended as first-line therapy in
clinically stable patients with heart failure if their ven-
tricular dysfunction is not severe. Glitazones are contra-
indicated in patients with heart failure due to an
increased risk of exacerbations [16-19]. Therefore, most
of the available systematic reviews focused either on pa-
tients with diabetes already diagnosed with heart failure
and compared metformin with other T2DM treatments
[20-22] or on the risk of heart failure associated with
rosiglitazone compared with pioglitazone [23,24]. An-
other systematic review evaluated the risk of heart fail-
ure associated with other drug comparisons, but did not
numerically summarize the findings [25]. The effects of
blood glucose-lowering drugs on the risk of heart failure
in routine clinical practice, other than the risk observed
for glitazones, has not been systematically reviewed and
integrated.
The present research effort is part of the Safety Evalu-
ation of Adverse Reactions in Diabetes (SAFEGUARD)
project (http://www.safeguard-diabetes.org/). The goal of
SAFEGUARD is to evaluate the cardiovascular and pan-
creatic safety of oral blood glucose-lowering medications
in patients with T2DM. For this purpose, the project in-
cludes an ongoing observational study of aggregated data
from more than 1.7 million patients in Europe and the
USA, the systematic review of available evidence from
published observational studies and clinical trials, and
the implementation of state-of-the-art mechanistic stud-
ies. Systematic reviews were performed separately for
observational studies and clinical trials as recommended
by the Cochrane Handbook for Systematic Reviews of In-
terventions [26]. In this report, we summarize the results
of a systematic review of published observational studies
on the risk of heart failure to address the above-
mentioned gaps.
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The methods used to define the specifications for search,
selection, abstraction, quality assessment, data synthesis,
and analysis of the published literature are described
below.
Literature search
We conducted a systematic literature search in Medline,
Embase, and the Cochrane Library with medical subject
headings (MeSH) terms and free-text words for noninsu-
lin blood glucose-lowering drugs, heart failure (the focus
of this research), and other cardiovascular outcomes
(acute coronary syndrome or acute myocardial infarction,
stroke, cardiovascular death, ventricular arrhythmia, and
sudden cardiac death), which are being evaluated in a sep-
arately review. The search was conducted on November
11, 2011, and was limited to observational studies on
humans, including systematic reviews, meta-analyses, and
original articles, with no publication date or language
restrictions (Medline search terms are included in the
Additional file 1). Reference lists of systematic reviews and
meta-analyses identified during the study selection process
were examined for eligible studies not previously iden-
tified. We conducted an updated literature search in
September 2014, and the impact of the fewer additional
studies that were identified is reported in the Discussion
section.
Study selection and data abstraction
Studies were eligible if they were cohort or case–control
studies on individuals with T2DM and provided relative
risk estimates of heart failure comparing two or more
noninsulin blood glucose-lowering drugs, in monother-
apy or combination therapy, individually or combined in
drug classes. Relative risk estimates had to be adjusted,
at a minimum, for age and sex. If relative risk estimates
were not provided but data were presented to enable
estimation of age-and-sex-adjusted relative risks, the
study was considered eligible. No exclusion criteria
were implemented.
Titles and abstracts were reviewed for study eligibility
by at least two researchers. Disagreements were solved
by consensus with a third researcher. Selected studies
underwent full-text review for final selection decisions.
Data were abstracted by one researcher using standard-
ized data collection forms in Microsoft Access and Excel
designed a priori for the present study and adapted after
a pilot test. A second researcher reviewed the extracted
data for accuracy and completeness. Disagreements were
solved by consensus.
When results of any given comparison were available
from more than one study on largely overlapping study
populations, we selected the most recent study. Within
each study, when multiple results were available, weselected those with the longest observation period and
the most extensive covariate adjustment. Results com-
paring drugs of interest and insulin were retained as
long as the study population consisted of individuals
with T2DM, but results comparing drugs of interest to
untreated subjects were not abstracted. When the data
to extract from an article appeared only in figures in the
original study, or for clarifying information for study in-
clusion decisions, authors of a few studies were con-
tacted with requests for point estimates and confidence
intervals.
Quality assessment
We assessed the quality of each study included in the
systematic review using two tools that investigate the
risk of bias in several domains, the Newcastle-Ottawa
Quality Assessment Scale (NOS) [27] and the RTI
item bank on risk of bias and precision [28,29]. (See
Additional file 1 for a detailed description of the two
instruments). We tailored both tools to the topic of
this systematic review. The tools were applied to each
article separately by two researchers (MP, NR, or
AVM); disagreements were solved by consensus. Find-
ings of high and unclear risk of bias for each individ-
ual study based on the RTI item bank are displayed in
graphs in Additional file 1.
Data synthesis and analysis
Quantitative analysis was conducted using Review Manager
(RevMan) software version 5.2.3 (The Nordic Cochrane
Centre, Copenhagen). For each comparison with at least
three independent point estimates available, we estimated
summary relative risks and 95% confidence intervals (CIs)
for heart failure using both random and fixed-effects
models [30]. We inverted some reported relative risks
within the same comparison group to use a common
reference drug; for example, converting the comparison
of pioglitazone versus rosiglitazone into rosiglitazone
versus pioglitazone.
We generated forest plots that included adjusted rela-
tive risks and weights for pooled analysis for individual
studies, as well as the effect size estimate (95% CI) for
the aggregated results under the random effects model.
If within a given study and for a given comparison, re-
sults were reported separately for monotherapy and
combination therapy, we estimated the summary relative
risk using fixed-effects models for inclusion in the over-
all forest plot. If the groups did not include independent
subjects, the group with the most precise relative risk
was included in the forest plot. Where statistical meta-
analysis was not appropriate due to insufficient data,
relative risk estimates from each study were reported
separately. In the overall forest plot, for completeness,
we provided the summary relative risk estimate based on
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heterogeneity was assessed by graphical inspection of
forest plots and with Cochran’s χ2 test of homogeneity.
Tau2 is also presented as an estimate of the between-
study variance when there was statistical evidence of
heterogeneity (P value < 0.10) according to the χ2 test
from the random-effects models. The Higgins I2 statistic
was used to describe the percentage of between-study
variability estimates of the total variability that is attrib-
utable to true heterogeneity rather than chance; a
threshold of 50% was considered indicative of substantial
to considerable heterogeneity [31].
To explore sources of heterogeneity and better under-
stand the evidence, we implemented subgroup analyses
designed a priori. When possible, we stratified according to
study design, regimen (monotherapy only and combined
therapy), type of drug use (new users and all users including
prevalent users), type of event (incident heart failure only
and combined incident plus prevalent heart failure), and
finally the age range of the source population. The χ2 testFigure 1 Flow Diagram of Study Identification and Selection Process.
contributed to more than one drug-drug comparison.was used to test for homogeneity between subgroups.
When stratification was not possible due to the number of
studies, we restricted the analysis to one of the study sub-
groups (i.e., new users only).
Publication bias was examined by visual evaluation of
funnel plots.
The present report follows MOOSE (Meta-analysis Of
Observational Studies in Epidemiology) guideline/check-
list [32], which is included in the Additional file 1. The
present systematic review of published observational
studies does not require ethics approval.
Results
Study selection and characteristics of included studies
Figure 1 displays the study selection process. From the 44
studies selected for the systematic review of cardiovascular
outcomes, we identified 20 studies evaluating the risk of
heart failure [33-52] (see Table 1). Of these, 12 contributed
to the meta-analysis, with six drug comparisons: rosiglitazone
versus pioglitazone (5 studies) [33,34,37,43,44], rosiglitazoneNote: No study was added by cross-referencing. aSome studies
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http://www.biomedcentral.com/1471-2261/14/129versus metformin (3 studies) [36,40,42], pioglitazone versus
metformin (2 studies) [36,42], rosiglitazone versus sulfonyl-
ureas (1 study) [35], pioglitazone versus sulfonylureas (2
studies) [36,38], and sulfonylureas versus metformin (5
studies) [35,38,39,41,42]. The other 8 studies could not be
included in the meta-analysis due to the heterogeneity of
the comparisons, which often involved reference groups
combining several medications. One study was performed
in patients with diagnosed heart failure who were followed
for hospital readmission for heart failure or death [49].Figure 2 Heart Failure Relative Risk (Random Effects) in Blood Glucose-
IV = inverse variance. Note: For rosiglitazone versus metformin, the study
combination therapy and for Loebstein et al. [40], we included the fixed-effec
(see study reported estimates by subgroup in the Additional file 1). For sulfon
with the reported estimate for the second-generation sulfonylureas.All 12 studies contributing data to the meta-analysis were
cohort studies, with one reporting the results of a nested
case–control analysis. The vast majority of these studies de-
fined the outcome based on hospitalizations. Only 3 studies
also included outpatient diagnoses of heart failure in their
endpoint definition [33,39,42]. All of the studies included
the specific code for heart failure (i.e., ICD-9 428) in their
definition except one study that focused on acute heart fail-
ure [43]. Five studies were restricted to the evaluation of in-
cident heart failure [33,38,39,41,42]. The number of heartLowering Medications Users and RTI Item Bank Quality Assessment.
by Tzoulaki et al. [42] contributed with the relative risk reported for
t summary relative risk for monotherapy and combination therapy
ylureas versus metformin, the study by Tzoulaki et al. [42] contributed
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age ranges of the study populations with type 2 diabetes
varied but included only adults; the vast majority of studies
included a broad age range, while a few were restricted to
age 65 years or older [34,37,44]. The definition of exposure
varied across studies in terms of length of exposure, drug
combinations, drug comparisons, and statistical handling of
treatment changes.
Meta-analysis results with quality assessment
In Figure 2, the left panel displays the random-effect for-
est plot for all the drug comparisons included in our
meta-analysis. Fixed-effect models produced summary
estimates of similar magnitude to those of random-effect
models. Because we found across-study heterogeneity
within some comparisons, we present only the random-
effect estimates in the text unless mentioned otherwise.
Summary results of study quality assessment with the
RTI item bank for these 12 studies are provided in the
right panel. Detailed results of the NOS and the RTI
item bank for the 20 studies included in the systematic
review are available in Additional file 1: Tables S1e
through S3e. Overall, scores with the NOS for the 20
studies were between 5 and 9; the median and mode score
was 8. With the RTI item bank, 3 studies had a high risk of
bias for 25% or more of the items assessed [33,51,52]; and
2 additional studies had a high risk of bias for 20% or more
of the items assessed [45,47]. In our assessment, 4 studies
had the potential for immortal time bias [33,36,38,45,52], 8
studies might have been affected by confounding by indica-
tion [33,39,40,42,47,50-52], and 8 studies had unmeasured
confounding [33,38,39,42,43,47,51,52]. An overview of the
experience with and a comparison of the two tools is re-
ported elsewhere [53].Table 2 Risk of heart failure in Rosiglitazone users compared
Study (Author, Year) All users
Individual Studies
Chou [33] 0.82 (0.62-1.09)
Graham [34] 1.25 (1.16-1.34)
Juurlink [37] 1.30 (1.16-1.46)
Wertz [43] 1.12 (0.94-1.33)
Winkelmayer [44] 1.13 (1.01-1.26)
Meta-Analysis
Fixed effects, RR 1.20 (1.15-1.27)
Random effects, RR 1.16 (1.05-1.28)
Heterogeneity statistics τ2 = 0.01
χ2 = 11.81 (df = 4)
I2 = 66%
Df = degrees of freedom; RR = relative risk.Risk of heart failure in rosiglitazone users compared with
pioglitazone users
Five cohort studies contributed to evaluation of the risk
of heart failure in rosiglitazone users compared with pio-
glitazone users [33,34,37,43,44] (Figure 2). Patients were
included regardless of whether they were using other
blood glucose-lowering drugs. The summary relative risk
was 1.16 (95% CI, 1.05-1.28). Heterogeneity was present
(I2 = 66%). Of the five studies, one had high risk of bias
for 50% of the items evaluated [33]. It was the only study
with a point effect estimate below unity, and it included
prevalent users. When excluding this study in the suba-
nalysis restricted to new users [34,37,43,44] (Table 2 and
Additional file 1: Figure S1e), I2 went from 66% to 31%.
The fixed effects summary relative risk was 1.21 (95%
CI, 1.14-1.30) for new users. These studies defined the
outcome as hospitalization for heart failure and included
patients with or without prior heart failure. Only one
study provided results stratified by prior history of the
condition [44]. In that study, stratified results suggested
that, among patients without a prior history of heart fail-
ure, new users of rosiglitazone had a greater risk of heart
failure hospitalization than new users of pioglitazone
(relative risk, 1.21; 95% CI, 1.03-1.42), and patients with
prior heart failure did not experience increased risk
(relative risk, 1.04; 95% CI, 0.89-1.22).
The study populations in 2 studies included subjects
younger than 65 years or older. The random effects
summary relative risk of the 3 studies conducted in pa-
tients aged 65 years or older was 1.23 (95% CI, 1.14-
1.32) [34,37,44] (Table 2).
Overall, based on available studies, risk of heart failure
was about 20% greater for users of rosiglitazone than for
users of pioglitazone.with Pioglitazone users, overall and subgroup analyses
Relative risk (95% Confidence interval)
Subgroup analyses
New users New users, Aged ≥ 65 years
— —
1.25 (1.16-1.34) 1.25 (1.16-1.34)
1.30 (1.16-1.46) 1.30 (1.16-1.46)
1.12 (0.94-1.33) —
1.13 (1.01-1.26) 1.13 (1.01-1.26)
1.22 (1.16-1.28) 1.23 (1.17-1.30)
1.21 (1.14-1.30) 1.23 (1.14-1.32)
τ2 = 0.00 τ2 = 0.00
χ2 = 4.35 (df = 3) χ2 = 3.33 (df = 2)
I2 = 31% I2 = 40%
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metformin users
Based on 3 studies, the summary relative risk for rosigli-
tazone, as monotherapy or in combination with other
blood glucose-lowering agents, versus metformin was
1.36 (95% CI, 1.17-1.59) [36,40,42] (Figure 2). The rela-
tive risk for monotherapy was 1.42; (95% CI, 0.95-2.13)
and for combination therapy was 1.28 (95% CI, 1.08-
1.52) (see Additional file 1: Figure S2e). The effect esti-
mates for monotherapy were heterogeneous across the
three studies, I2 = 69%. Quality assessment results dis-
played on the right panel of Figure 2 show that 2 of the 3
studies had high risk of bias for about 20% of items and an
unclear risk of bias for an additional 20% of items [36,40].
Two of these studies evaluated the risk of heart failure in
pioglitazone users compared with metformin users, yield-
ing a summary relative risk of 1.14 (95% CI, 0.86-1.50); we
included these studies in the overall forest plot for com-
pleteness [36,42]. Overall, based on few studies, risk of
heart failure in users of rosiglitazone was about 40% higher
than in users of metformin, while the risk in pioglitazone
users was closer to the risk observed in metformin users.
Risk of heart failure in glitazones users compared with
sulfonylurea users
Information on the risk of heart failure in glitazone users
compared with sulfonylureas users was very scarce. The
only study evaluating the risk of heart failure in rosiglita-
zone users compared with sulfonylureas users reported a
relative risk of 1.22 (95% CI, 0.86-1.74) [36]. This esti-
mate was very similar to the summary relative risk of
1.30 (95% CI, 0.90-1.87) observed for pioglitazone usersTable 3 Risk of heart failure in sulfonylurea users compared w
Relative
Study Author, Year Overall Cohort studies Monotherapy
Individual Studies
Koro [39] 0.96 (0.78, 1.19) — 0.96 (0.78, 1.19
McAlister [41] 1.16 (0.96, 1.41) 1.16 (0.96, 1.41) 1.16 (0.96, 1.41
Horsdal [35] 1.23 (0.78, 1.96) 1.23 (0.78, 1.96) 1.23 (0.78, 1.96
Tzoulaki [42] 1.21 (1.13, 1.30) 1.21 (1.13, 1.30) 1.21 (1.13, 1.30
Karter [38] 1.43 (1.01, 2.04) 1.43 (1.01, 2.04) —
Meta-Analysis
Fixed-effects, RR 1.19 (1.12, 1.26) 1.21 (1.14, 1.29) 1.18 (1.11, 1.26
Random effects, RR 1.17 (1.06, 1.29) 1.21 (1.14, 1.29) 1.15 (1.04, 1.28
Heterogeneity statistics τ2 = 0.00 τ2 = 0.00 τ2 = 0.00
χ2 = 5.25 χ2 = 1.06 χ2 = 4.15
(df = 4) (df = 3) (df = 3)
I2 = 24% I2 = 0% I2 = 28%
Df = degrees of freedom; RR = relative risk.
aSulfonylurea and metformin in monotherapy.compared with sulfonylurea users [36,38] (Figure 2). The
study by Karter et al. [38], excluded patients with heart
failure events within the 3 prior years.
Risk of heart failure in sulfonylurea users compared with
metformin users
Five studies reported on the risk of heart failure in sulfo-
nylureas users compared with metformin users (Figure 2)
[35,38,39,41,42], but only 3 included the list of individual
sulfonylureas evaluated [39,41,42]. All were cohort stud-
ies, and 1 included a nested case–control analysis. One
study presented the effect estimates for treatment pe-
riods of first-generation and second-generation sulfonyl-
ureas separately [42]. For our main analysis, we included
the reported relative risk for second-generation sulfonyl-
ureas as they were most frequently used. The overall
random effect summary relative risk was 1.17 (95% CI,
1.06-1.29). Heterogeneity of effect estimates across stud-
ies did not look important (I2 = 24%). There was high
risk of bias for about 15% or less of the assessed items,
but in some studies, the risk of bias was unclear for an
additional 10% to 20% of the items. When in the analysis
we included the reported relative risk for the first-
generation sulfonylureas in the Tzoulaki et al. study in-
stead of that reported for the second-generation, the
overall random effect summary relative risk was 1.20
(95% CI, 1.04-1.39) [42], but with substantial heterogen-
eity (I2 = 53%).
The definition of current exposure varied largely
across studies, from use at index date [38,42] to use dur-
ing the last 90 days prior to the index date or presence
of at least 1 prescription in the study period [41].ith metformin users, overall and subgroup analyses
risk (95% confidence interval)
Subgroup analyses
a Incident heart failure New users New or prevalent users
) 0.96 (0.78, 1.19) — 0.96 (0.78, 1.19)
) 1.16 (0.96, 1.41) 1.16 (0.96, 1.41) —
) — — 1.23 (0.78, 1.96)
) 1.21 (1.13, 1.30) — 1.21 (1.13, 1.30)
1.43 (1.01, 2.04) 1.43 (1.01, 2.04) —
) 1.19 (1.12, 1.26) 1.22 (1.03, 1.44) 1.18 (1.11, 1.27)
) 1.16 (1.03, 1.31) 1.22 (1.02, 1.46) 1.13 (0.95, 1.33)
τ2 = 0.01 τ2 = 0.00 τ2 = 0.01
χ2 = 5.22 χ2 = 1.04 χ2 = 4.11
(df = 3) (df = 1) (df = 2)
I2 = 43% I2 = 4% I2 = 51%
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those of the overall analysis, when restricting analysis to
studies including only incident events (relative risk, 1.16;
95% CI, 1.03-1.31; n = 4) or reporting only on monother-
apy regimens (relative risk, 1.15; 95% CI, 1.04-1.28; n = 4)
(Table 3). Only 2 studies were restricted to new users,
yielding a summary relative risk of 1.22 (95% CI, 1.02-
1.46) (Table 3 and Additional file 1: Figure S3e) [38,41].
One study reported the effect of dose among users of
sulfonylureas and metformin. Monotherapy sulfonylurea
users exposed to high doses (defined as higher than the
median daily dose for each individual medication) were
more likely to develop heart failure than those using
lower doses (hazard ratio, 1.38; 95% CI, 1.20-1.60) [41].
For metformin, the hazard ratio was 1.06 (95% CI, 0.81-
1.41) comparing doses higher than the median daily dose
versus lower doses.
Overall, risk of heart failure in sulfonylurea users was
about 20% higher than the risk in metformin users.
Publication bias
Examination of the funnel plots does not suggest publi-
cation bias, although the number of studies was small for
all the comparisons evaluated. The funnel plot for studies
(n = 5) evaluating the risk of heart failure in rosiglitazone
users compared with pioglitazone users and in sulfonylurea
users compared with metformin users are both displayed in
Additional file 1. The apex in each funnel plot is pointing
up around a relative risk of 1.3 for each of these two
comparisons (Additional file 1: Figures S4e and S5e).
Discussion
This systematic review of published observational studies
on the risk of heart failure associated with noninsulin
blood glucose-lowering drugs in patients with T2DM
confirmed that studies in this field are very heterogeneous.
Therefore, summarizing the scientific evidence is challen-
ging. The lack of a common reference medication for
evaluation of all potential exposures across studies limited
direct comparison of effect estimates. Of the 20 studies
included in our systematic literature review, only 12 could
contribute to the meta-analysis. Our summary effect
estimates are compatible with a small increase in the risk
of heart failure among patients with T2DM using rosiglita-
zone compared with the risk in those using pioglitazone.
Users of glitazones were included whether or not they
were reported to use other blood glucose-lowering drugs.
Both glitazone users and sulfonylurea users seem to be at
increased risk of heart failure compared with metformin
users. Observational studies evaluating the risk of heart
failure of newer blood glucose-lowering agents were lack-
ing. Such studies are anticipated in light of the recent
unexpected results of the SAVOR_TIMI 53 trial reporting
that more patients in the saxagliptin group werehospitalized for heart failure than in the placebo group
(relative risk: 1.27; 95% CI, 1.07-1.51) [54]. A recent publi-
cation reported on sitagliptin users from an observational
study performed in a large USA claims database among
patients with diabetes and heart failure. Patients using
sitagliptin presented higher risk of hospital readmission
for heart failure than non–sitagliptin users [55]. However,
this study was not eligible for our meta-analysis because
the reference group includes all other glucose-lowering
agents combined.
The results of this meta-analysis are consistent with
published clinical trial information. A prior meta-
analysis of randomized, controlled clinical trials reported
that patients randomized to glitazones had a 2-fold
greater risk of heart failure than patients randomized to
placebo [56]. A large randomized clinical trial in patients
with T2DM and preexisting cardiovascular disease, the
PROactive study, reported that patients on pioglitazone
had serious heart failure events more frequently than
those on placebo [57]. In the RECORD clinical trial, pa-
tients on monotherapy with metformin or sulfonylureas
who were randomized to add-on rosiglitazone had twice
the risk of heart failure than those randomized to a com-
bination of metformin with sulfonylurea [58].
Most of the published meta-analyses of observational
studies have focused on patients with diabetes and heart
failure and concluded that glitazones are contraindicated
in these patients, while metformin can be safely used
[21,59]. A meta-analysis of observational studies per-
formed in patients with T2DM and treated with glita-
zones reported a risk of heart failure in users of
rosiglitazone almost 20% higher than the risk in users of
pioglitazone [24].
Heterogeneity and subgroup analyses
Although the studies included in our meta-analysis were
heterogeneous, all of the subgroup analyses performed
were compatible with the overall results. For example, in
the comparison of rosiglitazone and pioglitazone, the
analysis restricted to new users resulted in an effect esti-
mate of 1.21 (95% CI, 1.14-1.30), very close to the overall
hazard ratio of 1.16 (Table 2). The inclusion of prevalent
users can introduce bias caused by the underascertain-
ment of events that occur after the start of the therapy
but before the study start, which may lead to depletion of
susceptible patients, and by the inability to control for risk
factors that may be modified by the study drugs [60,61].
The conducted subgroup analyses consistently suggest
a greater occurrence of heart failure in rosiglitazone
users than in pioglitazone users.
Heart failure ascertainment
The majority of included studies defined the outcome
based on hospitalizations, and all except one study
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dictive value of ICD-9 code 428 as a primary diagnosis has
been reported to be 94.3% using the Framingham criteria
and 88.6% using criteria previously validated with pulmon-
ary capillary wedge pressure [62]. Since heart failure is a
complex and progressive syndrome whose recognition can
be obscured by a number of differential diagnoses, in stud-
ies without internal case validation we advise the use of
specific primary discharge codes for heart failure hospitali-
zations. Because of the progressive evolution from the ini-
tial symptoms and signs to overt congestive heart failure,
the onset date of heart failure is difficult to determine in
the absence of outpatient diagnoses. If relying only on
hospitalizations, severe events or heart failure exacerba-
tions will be captured, but milder episodes will be missed
because those episodes are diagnosed and stabilized in the
outpatient setting, most frequently in the elderly. Since
less than half of the studies were restricted to the evalu-
ation of incident heart failure [33,38,39,41,42], the other
studies might be affected by selection biases such as
contraindication bias due to chronic heart failure. For ex-
ample, metformin used to be contraindicated in patients
with heart failure, and risk effect estimates relative to met-
formin use in studies from that time might be potentially
biased toward the null or be negatively confounded. Our
summary effect estimate comparing metformin and sulfo-
nylurea users was not affected by this type of bias, since 4
of the 5 included studies evaluated incident events, and
the analysis restricted to these 4 studies yielded the same
effect estimate (Table 3).Role of biases in included studies
Observational studies are vulnerable to confounding and
selection and information biases; therefore, limitations
of the studies included in this meta-analysis could have
affected our main results.Depletion of susceptibles
The reported low effect estimate of 0.82 (95% CI, 0.62-
1.09) for rosiglitazone users compared with pioglitazone
users in one study [33] may be related to several biases,
including depletion of susceptibles. In this cohort study,
patients were included only if they were treated with gli-
tazones (prevalent or incident use) for more than
120 days within the first 180 days after the date of the
prescription. If rosiglitazone is associated with a greater
cardiovascular risk than pioglitazone, as is suggested by
our findings, and prevalent users are included, differen-
tial depletion of susceptible patients between the rosigli-
tazone and pioglitazone groups might account for the
apparent beneficial effect seen in rosiglitazone users
compared with pioglitazone users. That is, more rosigli-
tazone users than pioglitazone users might have beenexcluded from the study within the 120-day use criterion
due to early cardiovascular side effects.
Clinical guidelines and prescription patterns
The application of clinical guidelines could have oper-
ated in opposite directions over the years, as recommen-
dations changed over time. Common to all issued clinical
guidelines is the fact that the treatment of diabetes is
guided by disease severity and patient characteristics. Few
studies have accounted for disease severity; therefore, con-
founding by indication might be present in the majority of
the within-study comparisons of this meta-analysis. Most
of the comparisons with metformin could be affected by
this type of bias because metformin is recommended as
first-line therapy and is indicated for patients with less se-
vere disease. This might be relevant for the comparisons
between sulfonylurea and metformin users. The cardio-
vascular concerns for sulfonylureas dated back to the
1970s when the University Group Diabetes Program
(UGDP) was terminated prematurely because of an excess
of cardiovascular mortality associated with tolbutamide
(the first-generation sulfonylurea used in the study). A
special warning on the potentially increased risk of cardio-
vascular mortality associated with all sulfonylureas was is-
sued in the USA. The results of the UK Prospective
Diabetes Study (UKPDS), comparing the study sulfonyl-
ureas (chlorpropamide, glibenclamide, or glipizide) with
insulin, showed that the intensive blood-glucose control
with either sulfonylureas or insulin decreases the risk of
microvascular complications, but not macrovascular dis-
ease, in patients with type 2 diabetes. None of the individ-
ual drugs had an adverse effect on cardiovascular
outcomes. Later published observational studies on the as-
sociated risk of cardiovascular outcomes with the use of
sulfonylureas have been heterogeneous and with variabil-
ity on the individual sulfonylureas evaluated. Therefore,
the cardiovascular safety of sulfonylureas remains unclear.
As mentioned previously, the 2012 joint clinical guide-
lines of the ADA and the EASD emphasized that the
choice of blood glucose-lowering agent should focus on
drug safety, especially protecting against hypoglycemia,
heart failure, renal dysfunction, bone fractures, and drug-
drug interactions [15]. However, clinical guidelines have
been changing over time. Metformin and rosiglitazone
were previously contraindicated in patients with heart fail-
ure and were avoided to some extent in patients at high
risk of developing heart failure. At present, metformin is
being recommended as first-line therapy in clinically stable
patients with heart failure if their ventricular dysfunction
is not severe. Metformin is not recommended in patients
with severe renal or hepatic impairment because of the
risk of lactic acidosis. The cardiovascular safety of newer
blood glucose-lowering medications is less known [63]. As
a consequence of the aging of the population overall and
Varas-Lorenzo et al. BMC Cardiovascular Disorders 2014, 14:129 Page 14 of 17
http://www.biomedcentral.com/1471-2261/14/129improved survival after myocardial infarction, patients
with T2DM and progressive heart failure are now fre-
quently seen in clinical practice. The medical care of these
patients is challenging; their multiple comorbidities often
require treatment with several concomitant medications
and determine contraindications to various blood glucose–
lowering agents. Avoiding glitazones among patients at high
risk of or with existing heart failure is recommended in
clinical guidelines for both diabetes treatment and heart
failure control. Glitazones are known to cause sodium and
water retention and increased risk of worsening heart fail-
ure and hospitalization. Because of the impact of clinical
guidelines on prescribing patterns, the risk of heart failure
associated with metformin and glitazones might be under-
estimated in the evaluated published studies.Formulary restrictions
A similar bias is that imposed by formulary restrictions
in the health plans from which many of the study popu-
lations were drawn. For example, because at Maccabi
Healthcare Services rosiglitazone could be prescribed
only if there was an inadequate control of blood glucose
with sulfonylurea, metformin, or both, the heart failure
effect estimate for rosiglitazone versus metformin mono-
therapy in the study by Loebstein et al. [40] (relative risk,
2.23; 95% CI, 1.41-3.53) might be overestimated.Residual confounding
Residual confounding can be a major limitation for the
majority of the included studies since the magnitude of
the increased risks was rather small for most of the
comparisons. Residual confounding might be present in
studies that failed to systematically record some lifestyle
factors. Few studies adjusted for socioeconomic status or
education and physical activity, which can all be associ-
ated with both treatment selection and the development
of outcome. Metformin has been the medication of
choice for obese patients with T2DM since the results of
the United Kingdom Prospective Diabetes Study showed
a beneficial effect on the risk of myocardial infarctions
and diabetes-related deaths of initial therapy with met-
formin in overweight and obese patients [64]. The ma-
jority of the studies included in our meta-analysis failed
to completely adjust for indicators of obesity, which is
highly prevalent among the T2DM population. Due to
selective prescribing of metformin to overweight/obese
patients with T2DM and the known increased risk of
heart failure among obese patients, a higher absolute risk
of heart failure is expected among these patients. This
could bias the relative risk estimate towards the null
when other blood glucose-lowering agents are compared
with metformin.Intermediate factors
Glycemic indicators, such hemoglobin A1C, can be con-
sidered causal intermediate factors since they are related
to the effectiveness of the blood glucose-lowering drugs
and to the severity of diabetes, which is a risk factor for
cardiovascular complications. Several studies adjusted for
blood glucose indicators during patient follow-up, which
could underestimate the relative risk [33,35,40,48,52]. Fur-
ther, if they are considered potential time-varying con-
founders, appropriate statistical techniques should have
been applied [65]. For example, if levels of hemoglobin
A1C are measured periodically and determine treatment
decisions and future risk of heart failure, as treatment
will also modify the levels of hemoglobin A1C, use of
statistical techniques to account for this relationship is
warranted.Dose and duration effects
We were not able to evaluate the effect of dose and dur-
ation due to the scarcity of data in the published studies.
One study reported that sulfonylurea used at high doses
increased the risk of heart failure compared with lower
doses while results for metformin were inconclusive
[41]. Since blood glucose-lowering agents should be ini-
tiated at low doses and titrated up according to the de-
gree of glycemic control, clinical guidelines recommend
tailoring treatment to each patient. Therefore, dose and
treatment duration of each individual medication and
add-on medications are very important to evaluate safety.Literature search update
In September 2014, we updated the literature search
using the original search terms in PubMed. Embase and
the Cochrane Library, which had not identified any stud-
ies to include in the original systematic review beyond
those found in PubMed, were not searched in this up-
date. Three new studies were considered to be eligible
and were reviewed [66-68]; all provided results on the
comparison of rosiglitazone and pioglitazone users, and
one compared glitazone users with metformin users
[68]. The updated effect estimate for rosiglitazone com-
pared with pioglitazone users remained practically un-
changed, with a summary relative risk of 1.16 (95% CI,
1.03-1.30). For the comparison with metformin, the up-
dated summary relative risk was 1.42 (95% CI, 1.21-1.66)
for rosiglitazone and 1.12 (95% CI, 0.88-1.43) for pio-
glitazone, very similar to the values obtained in the ori-
ginal meta-analysis. A few more studies were reviewed
[55,69-71], but the reference groups without the medi-
cation of interest included all the other medications
combined and therefore were not eligible for our meta-
analysis.
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Our systematic review was carefully planned, and we in-
cluded in the meta-analysis only studies with a clear def-
inition of the reported comparisons, which should be
useful for clinicians making decisions on specific thera-
peutic alternatives for specific patients. In addition, our
detailed evaluation of the quality of each reviewed study
using the NOS and the RTI item bank helps to interpret
the results of heterogeneous studies evaluating the risk of
heart failure associated with each individual medication
from classes that are also very heterogeneous in their
mechanisms of action.
The main limitation of this meta-analysis was the het-
erogeneity in the design of the primary studies. Key
drivers of this heterogeneity were the complex array of
treatment options based on guidelines, formularies, vary-
ing diabetes severity status, and the outcome definitions.
The studies that combined medications (e.g., “any other
treatment”) as the comparison group are of particular
concern for this and future meta-analyses for two main
reasons. First, “any other treatment” represents different
treatments depending on the study period and popula-
tion, which decreases the applicability and comparability
of results. Second, results relative to such reference
treatment may not be useful for clinical decision makers
who need to choose between specific therapeutic alter-
natives. In addition, the lack of specific comparisons to
evaluate the risk of heart failure in users of each individ-
ual sulfonylurea makes difficult the interpretation of our
findings for this heterogenous group of medications.
Further studies of use of individual sulfonylureas on the
risk of heart failure are warranted.
Conclusions
In conclusion, the overall results of this meta-analysis
suggest that patients with T2DM using either glitazones
or sulfonylureas might be at greater risk of heart failure
than metformin users. However, indication bias might
account for part of the differential effect between these
medications.
Results from ongoing large multidatabase studies,
carefully planned and conducted, are awaited and will
help to elucidate the risk of heart failure in patients with
diabetes. These studies will evaluate newer available
blood glucose-lowering therapies.
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